168 related articles for article (PubMed ID: 35467016)
21. Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
Fujiwara Y; Sekine I; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Simmyo Y; Fukui T; Yamada K; Tamura T
Jpn J Clin Oncol; 2007 May; 37(5):358-64. PubMed ID: 17538190
[TBL] [Abstract][Full Text] [Related]
22. Optimal exposure to docetaxel in adjuvant chemotherapy for early-stage breast cancer.
Guo J; Lin W; Weng Y; Chen Y; Zeng S; Lin J; Zheng X; Li X; Lin M; Yu X; Chen Q
J Clin Pharm Ther; 2022 Dec; 47(12):2205-2213. PubMed ID: 36418195
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
Fernández-Teruel C; Lubomirov R; Fudio S
J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
[TBL] [Abstract][Full Text] [Related]
24. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Tsuboya A; Kubota Y; Ishida H; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Sasaki Y; Matsumoto N; Kondo Y; Tomoda Y; Kusuhara H; Fujita KI
Cancer Chemother Pharmacol; 2021 Sep; 88(3):543-553. PubMed ID: 34117512
[TBL] [Abstract][Full Text] [Related]
25. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
[TBL] [Abstract][Full Text] [Related]
26. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Clin Pharmacokinet; 2013 Dec; 52(12):1111-25. PubMed ID: 23828617
[TBL] [Abstract][Full Text] [Related]
27. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
28. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
Brendel K; Bekaii-Saab T; Boland PM; Dayyani F; Dean A; Macarulla T; Maxwell F; Mody K; Pedret-Dunn A; Wainberg ZA; Zhang B
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1550-1563. PubMed ID: 34750990
[TBL] [Abstract][Full Text] [Related]
30. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Oyaga-Iriarte E; Insausti A; Sayar O; Aldaz A
J Pharmacol Sci; 2019 May; 140(1):20-25. PubMed ID: 31105026
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Kweekel D; Guchelaar HJ; Gelderblom H
Cancer Treat Rev; 2008 Nov; 34(7):656-69. PubMed ID: 18558463
[TBL] [Abstract][Full Text] [Related]
32. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Crona DJ; Ramirez J; Qiao W; de Graan AJ; Ratain MJ; van Schaik RH; Mathijssen RH; Rosner GL; Innocenti F
Pharmacogenomics J; 2016 Feb; 16(1):54-9. PubMed ID: 25869015
[TBL] [Abstract][Full Text] [Related]
33. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Tanaka H; Saito K; Mino K; Izumi K; Harada M; Isobe H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1505-9. PubMed ID: 19755821
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
[TBL] [Abstract][Full Text] [Related]
37. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K; Saito Y; Maekawa K; Kim SR; Kaniwa N; Nishimaki-Mogami T; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Matsumura Y; Ohtsu A; Saijo N; Minami H
Cancer Chemother Pharmacol; 2010 May; 66(1):95-105. PubMed ID: 19771428
[TBL] [Abstract][Full Text] [Related]
38. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
39. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
40. Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
Jian W; Xue J; Yao Q; Chen R; Yao Y; Wang M; Zhou T
Cancer Chemother Pharmacol; 2022 Dec; 90(6):489-497. PubMed ID: 36271947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
